Special Session:  DNA Adducts in Risk Assessment
1:00 pm – 5:00 pm

With recent advances in analytical detection techniques for DNA adducts comes the need to address recurring questions about the mechanistic and toxicological relevance of low-concentration measured adducts.  Despite the abundance of research in this field, the diversity of opinions as to the role of DNA adducts in cellular processing, repair mechanisms, and mutagenesis (and vice versa) suggests the need for a mechanism to reach scientific consensus.  Concurrent with the increasingly widespread collection of DNA adduct measurements as human biomarker data, the scientific community is also currently debating the relevance of these data for risk assessment.  This special session will address activities undertaken by HESI to further public discussion and consensus on the use of DNA adducts for risk assessment.

Tentative Program

Welcome and Introduction:  
Ms. Syril Pettit or Dr. Michael Holsapple (HESI) (confirmed)

Speakers: 

Chair:  Dr. Bennett van Houten (US National Institute of Environmental Health Sciences) (confirmed)
Available Tools for Measuring DNA Adducts
          Dr. David Shuker (Open University, UK) (confirmed)
DNA Adducts in Risk Assessment 
          Dr. Elizabeth Martin (AstraZeneca) (confirmed)
US Regulatory Perspective 
          Dr. Julian Preston (US Environmental Protection Agency National Health and Environmental Effects Research Laboratory) (confirmed)
European Regulatory Perspective
          Dr. Peter Kasper (Federal Institute for Drugs and Medical Devices, Germany) (confirmed)

Panel Discussion:

Moderator:  Dr. Bobby Kroes (Utrecht University) (confirmed)
Rapporteur:  Dr. Jay Goodman (Michigan State University) (confirmed)

Panelists:
Dr. Jean Cadet (French Atomic Energy Commission) (confirmed)
Prof. Dr. Helmut Greim (University of Munich) (confirmed)
Dr. Ben Van Houten (US National Institute of Environmental Health Sciences) (confirmed)
Dr. Veronique Thybaud (sanofi-aventis) (confirmed)
Dr. Robert Baan (International Agency for Research on Cancer) (confirmed)